Long-term follow-up for an mRNA vaccine dose you already received
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This is a follow-up study that checks the long-term safety and health benefits of mRNA-3705 for people who took it in an earlier trial (or had to pause dosing due to COVID-19 vaccination). You may be invited if you completed the earlier study schedule or can transition early because you missed several doses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously took mRNA-3705 in another mRNA-3705 study (or you can switch early after missing more than 3 doses because of COVID-19 vaccination).
- You finished your last study checkup (end-of-treatment/end-of-study visit) within 10 days before starting this extension.
- Your study doctor thinks you are likely to benefit from continuing mRNA-3705.
- You don’t have any new health issue (lab abnormality or medical condition) that could make the study riskier for you.
- You have not had a liver or kidney transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a follow-up study for people who already received the mRNA-3927 vaccine in an earlier trial. It looks at how safe the treatment is over the long term and whether it continues to have benefit.
This study tests a new type of COVID-19 vaccine that is designed to train your immune system to make stronger, longer-lasting protection. You may be able to join if you are 40–64, have already had at least two doses of a mRNA COVID-19 vaccine (Pfizer or Moderna) more than 4 months ago, and are generally healthy.
This trial tests an mRNA medicine (mRNA-3927) in people with propionic acidemia (PA). It aims to see whether this treatment is safe and can help the body when PA is confirmed by genetic testing.
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
This study checks how people with severe hemophilia A are doing over time after joining a previous BioMarin study of BMN 270. It helps researchers understand long-term safety and outcomes and may support your ongoing care plan.
This is an early-stage trial testing a new type of treatment called mRNA therapy that helps your body make missing proteins. Researchers are enrolling healthy volunteers to understand how safe and well-tolerated this approach is.
Hear when a new Methylmalonic Acidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.